Medicamen Biotech Limited
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations
What Medicamen files
- Others34
- Important22
- Board Meeting14
- Dividend/Bonus3
- Results2
- Insider Trade1
Medicamen Biotech Limited has informed the Exchange about Copy of Newspaper Publication
Medicamen Biotech's FY26 saw consolidated revenue grow 21.66% to ₹197.77 Cr, with PAT jumping 49.43% to ₹9.80 Cr. Domestic sales surged 71% via Medicamen Life Sciences. Key developments include international expansion, CDMO wins, and oncology division growth. The company incurred ₹1.18 Lakh in fines for compliance issues.
Medicamen Biotech reported FY26 turnover of ~178.85 Cr & PAT of ~9.41 Cr, with 80% sales from global markets. The company boosted R&D/Capex for sustainability and increased MSME sourcing. A `7,080 fine for a minor filing delay was noted and resolved. Loans to related parties significantly increased.
Medicamen Biotech's Board has proposed a final dividend for FY25-26, awaiting shareholder approval at the 33rd AGM. Book closure and record date for dividend eligibility are set.
Medicamen Biotech Limited has informed the Exchange about Copy of Newspaper Publication